Treatment Options

The goal of treatment for hemophilia A is to replace the missing clotting factor (factor VIII) in order to stop and prevent bleeding.1

Treatment for Moderate and Severe Hemophilia A1,2

The main treatment for moderate and severe hemophilia A is factor VIII replacement therapy. There are two types of factor VIII products: human plasma-derived factor VIII and recombinant factor VIII. Both of these options are effective and a healthcare provider can help the patient decide which option is best.

Factor VIII replacement therapy involves infusing the missing clotting factor directly into the bloodstream. Factor VIII infusions may be given1:

  • As needed to stop bleeding when it occurs (on-demand therapy)
  • On a regular basis to prevent bleeding (prophylactic therapy)

Learn about FVIII replacement therapy with Koāte-DVI » and ask your doctor if Koāte-DVI is right for you.

Koate-DVI is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.

References: 1. Dargaud Y, Negrier C. Haemophilia therapies. Expert Opin Biol Ther. 2007;7:651–663. 2. National Hemophilia Foundation website. MASAC Document #205: Recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. Accessed September 17, 2014.